Arlenda S.A. takes a step outside Europe announcing Arlenda Inc. as their U.S. subsidiary.

In the hotly competitive pharmaceutical sector, Arlenda SA(Spin-off – University of Liège, Belgium) is challenging their ability to create a space for themselves on the US market. In November 2011, Bruno Boulanger (CEO, Arlenda SA), and Tim Schofield (Managing Director, Arlenda, Inc.) announced the opening of the North American subsidiary Arlenda Inc., based in the University City Science Center in Philadelphia.

Known for their innovative software and statistical expertise, bridging the gap between Europe and the States is an exciting new development for the company. Originally created in 2003 by a multidisciplinary team of experts from analytical, statistical, pharmaceutical and software development fields of activity, Arlenda specializes in Applied « Modeling & Statistics » for informed and timely decision making in Life Sciences. Their diverse expertise and experience gives them the unique birds-eye perspective on the drug development process necessary to make connections between laboratories, manufacturing and clinical studies.

According to Boulanger (CEO, Arlenda SA), the objectives of this transatlantic step are threefold; to penetrate the American market with their expertise, to develop in the domain of Quality by Design and to promote the visibility of established quality-driven software. The adventure, appropriately code-named “Project Columbus”, in its developing stages, takes an interesting stance according to Schofield, by focusing on one question:

“How can we make the customer more competitive?”

Schofield, who heads Arlenda’s nonclinical statistics venture in Philadelphia, believes that by aligning services and anticipating software to match customer’s needs – rather than naively surrendering to their wants – is what gives this company an innovative approach in promoting state-of-the art pharmaceutical-oriented development.

Having in recent years made a brand name for themselves with software geared towards the validation of analytical methods, Arlenda is now proving that versatility is an open frame of mind that can become the pulse and inspiration behind new and exciting endeavours.

A practical example of where expertise and software unite is in the development of Stab.e.lity. Stab.e.lity is a software concept aimed at the evaluation of data collected from stability studies. According to the FDA, stability data that did not clearly support the expiration date was one of the foremost reasons for drug retractions in 2004. This emphasizes the true necessity for products founded on science. Simultaneously this helps customers provide the information required to meet regulatory bodies’ needs while empowering them to keep their products on the market. Written using the statistical programming language SAS, the Stab.e.lity software is a program that one can easily access through a web-interface. In other words by clicking on a URL one has access to the Stab.e.lity login page, turning the popular phrase “cloud-computing” into a tangible reality.

This opportune combination of creativity and science is possibly just the right blend that will further Arlenda’s endeavours to gain a permanent foothold on the shores of the continent which Christopher Columbus so fittingly named the “New World”.

Also important to note, Tim Schofield, Managing director of Arlenda Inc., will be attending the 2012 BIO International Convention in Boston June 18-21.